Oppenheimer raised the firm’s price target on iRhythm (IRTC) to $225 from $175 and keeps an Outperform rating on the shares. The firm notes Q3 revenue came in at $193M, bucking the seasonal trend and ahead of its/consensus $184M/$185M estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm price target raised to $235 from $220 at Baird
- iRhythm price target raised to $215 from $195 at BTIG
- iRhythm price target raised to $242 from $205 at Citi
- iRhythm price target raised to $212 from $193 at Canaccord
- Irhythm Technologies: Strong Q3 Performance and Positive Outlook Justify Buy Rating